Sources Sought/RFI Innovations in Malaria Vaccines and Biologics Development (IMVB)
Closed Pre-Solicitation Posted
- Solicitation number
- SS-RFI-7200AA-25-IMVB
- Agency
-
Bureau for Management
Washington Office, US Agency for International Development
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- Not on record
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The United States Agency for International Development (USAID) Bureau for Management is seeking support for its Malaria Vaccine Development Program through the Innovations in Malaria Vaccines and Biologics (IMVB) activity. The primary objective is to develop malaria vaccines and monoclonal antibodies that can reduce morbidity and mortality caused by Plasmodium falciparum infection. The contract will focus on strategic research to develop prototype vaccines targeting pre-erythrocytic and erythrocytic stages of the parasite life cycle, with the goal of improving upon currently recommended WHO vaccines in terms of efficacy, durability, and affordability. Potential contractors must operate under NAICS code 541715 for research and development in physical, engineering, and life sciences. Responses to the Sources Sought/Request for Information (RFI) are due by January 3, 2025, at 5:00 PM EST, with submissions to be sent to imvb@usaid.gov.
The pre-solicitation notice does not indicate a specific set-aside for small businesses, though small businesses are encouraged to respond. The estimated contract value ranges between $25-50 million, with an anticipated contract duration of 5-10 years. The IMVB activity will encompass three primary workstreams: next-generation CSP vaccines, blood stage vaccines, and combined CSP and blood stage approaches. Contractors will be responsible for implementing R&D projects, coordinating scientific meetings, procuring research materials and supplies, and providing technical support services. The ultimate aim is to develop vaccine candidates that meet the World Health Organization's Preferred Product Characteristics for malaria vaccines, potentially supporting research on monoclonal antibodies for improved vaccine development and passive protection against malaria.
Notice text
The purpose is to support the efforts of the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP) to develop malaria vaccines or monoclonal antibodies (mAbs) that reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. The Innovations in Malaria Vaccine and Biologics (IMVB) activity is a part of the MVDP portfolio that will support strategic research of new or improved malaria vaccines that target the pre-erythrocytic and/or erythrocytic stages of the parasite life cycle that will include prototype vaccine development, preclinical studies, and/or early clinical studies of promising vaccine candidates that offer improvements in efficacy, durability, and affordability over the currently WHO-recommended vaccines, with hopes of meeting the World Health Organization’s (WHO) Preferred Product Characteristics (PPCs) for malaria vaccines. The activity may also support research on mAbs for use in development of improved malaria vaccines and passive protection against malaria.
Files
| File | Type | Posted |
|---|---|---|
| SS-RFI-7200AA-25-IMVB.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity